Abstract
The long noncoding RNA (lncRNA) LINC00152, also known as CYTOR, displays aberrant expression in various cancers. However, its clinical value and functional mechanisms in breast cancer remain insufficiently understood. Our study found that LINC00152 is significantly upregulated in breast cancer, and that it acts as an indicator of poor survival prognosis. Further studies revealed that LINC00152 knockdown suppresses cell proliferation and tumorigenicity in vitro and in vivo. Mechanistic analyses demonstrated that LINC00152 directly binds to KLF5 protein and increases KLF5 stability. Moreover, LINC00152 is also a KLF5-responsive lncRNA, and KLF5 activates LINC00152 transcription by directly binding to its promoter. Our study suggests that LINC00152 promotes tumor progression by interacting with KLF5. LINC00152 may be a valuable prognostic predictor for breast cancer, and the positive feedback loop of LINC00152-KLF5 could be a therapeutic target in pharmacological strategies.
Highlights
Breast cancer accounts for the most common type of malignant tumor in women [1, 2]
The data showed that the patients with relatively high LINC00152 expression (>median level) exhibited poorer prognosis than those with low LINC00152 expression (Figure 1E), suggesting that LINC00152 is overexpressed in breast cancer and is related with bad clinical outcome
Our result found that overexpression of LINC00152 significantly facilitated the proliferation of breast cancer cell, whereas knockdown of KLF5 did not induce cancer cell proliferation (Figure 6A)
Summary
Breast cancer accounts for the most common type of malignant tumor in women [1, 2]. A potential biomarker needs to be urgently identified and its predictive molecular mechanisms in breast cancer understood. The Long noncoding RNAs (lncRNAs) was a RNA gene products which consist of 200 to 100,000 nucleotides. These transcripts have been recently identified to be largely functional but mechanistically unexplored, especially in human cancers [3]. Recent evidence reveals that lncRNAs are involved in breast cancer tumorigenicity [4,5,6]. The precise mechanism by which lncRNAs regulate breast cancer tumorigenicity remains largely unknown
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
